Results showed that following the six weeks of supplementation with the black seed oil decreased systolic blood pressure by 11.2% and diastolic blood pressure by 12.2%.
Photo © Shutterstock.com/Ulada
A study recently published in Food Science & Nutrition Research1 found that supplementation with a standardized black seed oil (ThymoQuin from TriNutra; Harrison, NY) supported blood pressure in healthy subjects. In the study, 20 subjects with normal blood pressure were all treated with a daily doses of black seed oil for six weeks. Following a three-week washout period, patients were given a placebo treatment for another six weeks. Subjects had their blood pressure tested daily throughout the study.
Results showed that following the six weeks of supplementation with the black seed oil decreased systolic blood pressure by 11.2% and diastolic blood pressure by 12.2%. An initial significant decline in blood pressure was observed in as little as two days. Following six weeks of placebo, subjects’ blood pressure elevated slightly.
“Almost a third of the adult population in America experience hypertension, and natural products, including Nigella sativa oil, have long been considered as a therapeutic remedy in many traditional medicine practices across the world,” said Morris Zelkha, CEO of TriNutra, in a press release. “This study demonstrated how ThymoQuin can help provide significant improvement towards healthy blood circulation measurements, which has not been seen from other more common varieties of black seed oil.”
ThymoQuin’s exclusive North America distributor is Barrington Nutritionals.
1. Bush B et al. “Effects of Standardized Black Seed Oil Cold Press Supplement Over A Six Week Period on Blood Pressure and Heart Rate in Healthy Patients: A Nonrandomized Clinical Trial.” Food Science & Nutrition Research, vol. 3, no. 1 (2020):1-5
Sirio Pharma launches line of ready-to-market organic gummies and softgels called PureOrganix
August 26th 2024The new line is made up of three gummies and one softgel that are formulated to meet stringent EU-Organic certification criteria, and target women’s health, metabolic health, and heart health.
SourceOne Global Partners to distribute Qualitas Health’s microalgae omega-3 ingredient globally
August 15th 2024SourceOne Global Partners has announced a partnership with Qualitas Health Inc., (dba iwi life) to introduce the company’s trademarked AlmegaPL microalgae omega-3 ingredient to the global marketplace.
Meta-analysis does not find increased risk of bleeding events from omega-3 PUFA consumption
July 8th 2024Researchers reviewed 11 studies and found that there was no difference in the incidence of bleeding events between patients receiving omega-3 PUFAs and those not receiving them. High dose EPA consumption was associated with an elevated but modest risk.